GSTM1 and ovarian cancer: The differences in rates of Hb increase may reflect differences in baseline Hb for the populations in the various studies; the mean baseline Hb of 10.7 g dl−1 for ovarian cancer patients in our study was somewhat higher than that for patients in two of the other studies (range: 9.5–9.9 g dl−1).